Physician profile
Michael M Sutton
NPI 1710543772
$2,056.86
in general payments reported to CMS, 2019-2025
18 companies · $562 in 2025
The $562 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $111 · 2023: $431 · 2024: $953 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $538.38 | 2024-2025 | Axios, Resolution 360 Clip, Exalt Model D |
| Medtronic, INC. | $315.28 | 2023-2024 | Endoflip |
| Janssen Biotech, INC. | $258.17 | 2023-2025 | Stelara, Tremfya |
| Abbvie INC. | $177.93 | 2022-2025 | |
| Celltrion USA INC. | $131.95 | 2024 | Zymfentra |
| Cook Medical LLC | $126.86 | 2023 | Hemospray |
| Madrigal Pharmaceuticals | $107.56 | 2025 | Rezdiffra |
| Olympus America INC. | $87.38 | 2024-2025 | Olympus, Endoclot Sis, Single Use Repositionable Clip |
| Erbe USA INC | $84.89 | 2023 | Erbe Vio3 |
| Pfizer INC. | $42.49 | 2025 | |
| Fujifilm Healthcare Americas Corporation | $36.55 | 2025 | |
| Aimmune Therapeutics, INC. | $32.75 | 2025 | Zenpep |
| Novo Nordisk INC | $28.86 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $19.93 | 2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $19.04 | 2025 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $16.64 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.50 | 2025 | Relistor |
| Gilead Sciences, INC. | $15.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.